EBRD, CDC, and DPI Formed Egyptian Generic Drug Platform

Posted on 11/28/2020

The European Bank for Reconstruction and Development (EBRD) is a founding investor on the creation of a US$ 750 million biopharmaceutical platform to broaden access to vital specialty generic drugs in Egypt with the potential to expand into other countries in Africa. This first of its kind pharmaceutical platform will generate significant cost savings for healthcare providers in Egypt. The platform also has ambitions to broaden the range of therapeutics available in other underserved markets in Africa.

The platform has raised an initial US$ 250 million from its founding investors – EBRD, CDC Group, and Development Partners International (through ADP III fund). The money has been used to fund the acquisition and combination of Adwia Pharmaceuticals, an Egyptian generic drugs manufacturer, and Celon Laboratories Pvt, an Indian oncology and critical care specialist.


Global law firm White & Case LLP has advised the European Bank for Reconstruction and Development (EBRD) on backing the platform.

EBRD is a multilateral bank that promotes the development of the private sector and entrepreneurial initiative in 38 countries across three continents. It is owned by 69 countries as well as the EU and the EIB. Egypt is a founding member of the EBRD. Development Partners International is a pan-African private equity firm.

Get News, People, and Transactions, Delivered to Your Inbox